首页 | 本学科首页   官方微博 | 高级检索  
检索        


Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K
Authors:Palmer James T  Bryant Clifford  Wang Dan-Xiong  Davis Dana E  Setti Eduardo L  Rydzewski Robert M  Venkatraman Shankar  Tian Zong-Qiang  Burrill Leland C  Mendonca Rohan V  Springman Eric  McCarter John  Chung Tobee  Cheung Harry  Janc James W  McGrath Mary  Somoza John R  Enriquez Philip  Yu Z Walter  Strickley Robert M  Liu Liang  Venuti Michael C  Percival M David  Falgueyret Jean-Pierre  Prasit Peppi  Oballa Renata  Riendeau Denis  Young Robert N  Wesolowski Gregg  Rodan Sevgi B  Johnson Colena  Kimmel Donald B  Rodan Gideon
Institution:Celera Genomics, Inc., 180 Kimball Way, South San Francisco, California 94080, USA. jim.palmer@celera.com
Abstract:We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号